Newswire (Published: Monday, June 19, 2017, Received: Thursday, June 15, 2017, 8:03:26 PM CDT)

Word Count: 357

By a News Reporter-Staff News Editor at Clinical Trials Week -- ASCO Perspective

"For men who are diagnosed with advanced prostate cancer, treatment has evolved into more effective approaches, first with chemotherapy and now with abiraterone," said Sumanta Kumar Pal, MD, ASCO Expert. "This is good news because using abiraterone could help many people live longer with fairly few additional side effects."

CHICAGO - Adding abiraterone acetate (Zytiga) plus prednisone to standard hormonal therapy for men newly diagnosed with high-risk, metastatic prostate cancer lowers the chance of death by 38%. In a phase III clinical trial of 1,200 men, abiraterone also more than doubled the median time until the cancer worsened, from 14.8 months to 33 months. The study will be featured in a press briefing today and presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting (see also Oncology - Prostate Cancer).

"There is a large unmet need to improve treatment for men with newly diagnosed metastatic cancer, who die of the disease within less than five years on average," said lead study author Karim Fizazi MD, PhD, head of the Department of Cancer Medicine at Gustave Roussy, University Paris-Sud in Villejuif, France. "The benefit from early use of abiraterone we saw in this study is at least comparable to the benefit from docetaxel chemotherapy, which was observed in prior clinical trials, but abiraterone is much easier to tolerate, with many patients reporting no side effects at all."

Prostate cancer growth is fueled by testosterone. Androgen deprivation therapy, or ADT, is active against prostate cancer by preventing testicles from making testosterone. Despite ADT, the adrenal glands and prostate cancer cells continue making small amounts of androgens. Abiraterone stops production of testosterone throughout the body by blocking an enzyme that converts other hormones to testosterone. The FDA previously approved abiraterone for patients with metastatic prostate cancer that worsened despite ADT.

Keywords for this news article include: Prostatic Neoplasms, Diagnostics and Screening, Metastatic Prostate Cancer, Oncology - Prostate Cancer, American Society of Clinical Oncology.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC


The American Society of Clinical Oncology Inc




North America
Western Europe
United States


Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Health Sciences
            Pharmaceutical Development
      Medical and Pharmaceutical Regulation
            Drug and Device Approval Process
                  Drug Testing and Approval Process
      Treatments and Therapies
            Medicinal Drugs
                  Drug Testing and Approval Process